Table 2. Renal insufficiency among the BIRMA cancer patients according to the K/DOQI, KDIGO classification (NKF, 2002; Levey et al, 2005).
| aMDRD–GFR (ml min−1 per 1.73 m2) | General population (n=1218) | Chemotherapy-naïve patients (n=302) | Not chemotherapy-naïve patients (n=916) | Comparison: chemotherapy-naïve vs not chemotherapy-naïve |
|---|---|---|---|---|
| ⩾90, n (%) | 358 (29.4) | 122 (40.4) | 236 (25.8) | <0.0001 |
| 89–60, n (%) | 583 (47.9) | 122 (40.4) | 461 (50.3) | 0.002 |
| 59–30, n (%) | 182 (14.9) | 37 (12.3) | 145 (15.8) | >0.05 |
| 29–15, n (%) | 11 (0.9) | 3 (1.0) | 8 (0.9) | >0.05 |
| <15, n (%) | 3 (0.3) | 2 (0.7) | 1 (0.1) | >0.05 |
| No SCR available, n (%) | 81 (6.7) | 16 (5.3) | 65 (7.1) | >0.05 |
Abbreviations: aMDRD=abbreviated Modification of Diet in Renal Disease formula; BIRMA=Belgian Renal Insufficiency and Anticancer Medications; GFR=glomerular filtration rate; K/DOQI=Kidney Disease Outcomes Quality Initiative; KIDGO=Kidney Disease: Improving Global Outcomes.